Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.

Name: Kaimen Rigor review — p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.
Item: p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.
Rating: 96
Author: Alpha1

Shanks HRC, Chen K, Reiman EM, Blennow K, Cummings JL, Massa SM, Longo FM, Börjesson-Hanson A, Windisch M, Schmitz TW

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.

Shanks HRC, Chen K, Reiman EM, Blennow K, Cummings JL, Massa SM, Longo FM, Börjesson-Hanson A, Windisch M, Schmitz TW

Read full text (PMC)

DOI

10.1038/s41591-024-02977-w

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/e3b5deee-2551-4be8-bcea-99860f754a0a" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/e3b5deee-2551-4be8-bcea-99860f754a0a/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

dce37d8540171e76bda27641bbb110037d91a3ba36a19845b96925d6e52d7e9f

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.

Shanks HRC, Chen K, Reiman EM, Blennow K, Cummings JL, Massa SM, Longo FM, Börjesson-Hanson A, Windisch M, Schmitz TW

Paper source

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim is based on surrogate biomarkers (CSF Aβ42, Aβ40, SNAP25, NG, YKL40, sMRI gray matter volume, FDG PET glucose metabolism) without demonstrating target engagement at the tested dose or citing validated evidence linking these surrogates to clinical outcomes. The paper acknowledges lack of direct p75NTR engagement markers and no significant cognitive effects.
“Currently, in vivo markers of direct p75 NTR engagement in humans are lacking. However, the CSF, sMRI and PET biomarkers included in this trial were prespecified on the basis of preclinical research examining pathways and mechanisms regulated by p75 NTR”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effects are small percentage changes in biomarkers (e.g., Aβ42 -6.98%, SNAP25 -19.20%, NG -9.17%) with no anchor to clinical meaningfulness. The paper states no significant cognitive effects and acknowledges the study was not powered for cognitive outcomes.
“Although the effect was not statistically significant, 26-week treatment with LM11A-31 produced up to 50% slowing of cognitive decline relative to that observed in the placebo group”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 2a randomized controlled trial of LM11A-31 in Alzheimer disease. The paper demonstrates strong scientific premise, rigorous design, and transparent reporting, with only minor gaps in data/code availability and some statistical reporting imprecision.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal housing, cell line authentication) due to the human clinical trial nature. The reviewers diverged slightly on exact p-value reporting and software identification, but these were minor and did not affect the overall status.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction thoroughly reviews prior research on p75NTR as a therapeutic target, including preclinical studies of LM11A-31, and acknowledges limitations of existing AD therapies. The rationale for targeting p75NTR is logically developed, and the study hypothesis follows directly from the cited evidence. The paper also addresses limitations of prior research by noting the lack of human testing and the need for a phase 2a trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing extensive prior work on p75NTR biology and LM11A-31, and clearly links this to the study's rationale and hypotheses.

Evidence

“Over the past two decades, multiple lines of evidence have converged on the p75 neurotrophin receptor (p75 NTR ) as a promising deep biology target for modifying neuronal dysfunction and degeneration in AD.”

Introduction ¶1Find in source

“we hypothesized that modulation of p75 NTR using LM11A-31 in persons with AD would be well tolerated and would slow AD progression, as measured by biomarkers of synaptic function, degeneration and glial activation”

IntroductionFind in source

“Despite its fundamental functional role in neural and developmental cell biology, the therapeutic potential for targeted modulation of p75 NTR in humans has not been tested.”

Introduction ¶6Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing extensive prior work on p75NTR and LM11A-31, and clearly links this to the study's rationale and hypothesis.

Evidence

paraphrase[Introduction, paragraphs 1-6]

“Over the past two decades, multiple lines of evidence have converged on the p75 neurotrophin receptor (p75NTR) as a promising deep biology target for modifying neuronal dysfunction and degeneration in AD.”

paraphrase[Introduction, final paragraph]

“On the basis of studies in preclinical AD-related mouse models and two prior safety and pharmacokinetic studies in healthy human participants, we hypothesized that modulation of p75NTR using LM11A-31 in persons with AD would be well tolerated and would slow AD progression.”

“A limitation of these strategies is that they each target a narrow set of AD-related pathophysiological processes.”

Introduction ¶1Find in source

The paper describes a randomized, double-blind, placebo-controlled, parallel-group design with 1:1:1 allocation. Randomization was performed using a list developed by Data Magik, with treatment center as a stratification variable. Blinding was maintained for sponsor, site personnel, participants, and caregivers. A priori power calculations were performed, and the sample size was adjusted based on a blinded review. Inclusion/exclusion criteria are detailed, and the analysis population (ITT) is defined. Outlier handling is described for biomarker analyses, and the trial includes appropriate controls (placebo). Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous, with clear randomization, blinding, sample size determination, and pre-specified inclusion/exclusion criteria.

Evidence

“Participants were randomized 1:1:1 into placebo, 200 mg LM11A-31 or 400 mg LM11A-31. The randomization list was developed by Data Magik and was structured to allow for a total of at least 240 participants (80 per group), with treatment center as the only stratification variable.”

MethodsFind in source

“The sponsor’s personnel, study sites’ personnel, participants and caregivers were blinded to the assigned treatment.”

MethodsFind in source

“These analyses determined that 51 participants per group were required to demonstrate an effect size of 0.56 between either dose of LM11A-31 and placebo with 80% power and a type 1 error rate of 0.05 (two-tailed)”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, sample size determination, and pre-specified inclusion/exclusion criteria.

Evidence

MethodsFind in source

“The sponsor’s personnel, study sites’ personnel, participants and caregivers were blinded to the assigned treatment.”

MethodsFind in source

The paper reports age, sex, race, MMSE score, CSF Aβ42, and APOE4 status in Table 1. Health status is addressed through inclusion criteria and baseline characteristics. Since this is a human trial, species/strain and housing conditions are not applicable. Sex is reported for both sexes, so a justification for single-sex is not applicable.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper reports key demographic and clinical characteristics of the trial participants, including age, sex, race, and health status.

Evidence

“Age | 72 (8.00) | 72 (7.75) | 72 (8.00) | H = 0.81 | 0.67 |”

Table 1Find in source

“Males, n (%) | 35 (43.2) | 38 (48.7) | 40 (48.2) | χ 2 = 0.60 | 0.74 |”

Table 1Find in source

“General health status acceptable for participation in a 26-week clinical trial”

MethodsFind in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, and key disease-related variables.

Evidence

“Age | 72 (8.00) | 72 (7.75) | 72 (8.00) | H = 0.81 | 0.67 |”

Table 1Find in source

“Screening MMSE | 22 (4.00) | 22 (5.00) | 23 (4.00) | H = 3.19 | 0.20 |”

Table 1Find in source

The paper explicitly names the IRBs that approved the study for each country (e.g., IRB00002556 for Austria) and states that the trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP. Informed consent is described as obtained before the screening visit. Regulatory compliance is stated by naming the Declaration of Helsinki and ICH-GCP.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper reports named IRB approvals for each participating country and states that informed consent was obtained.

Evidence

“The IRBs approving the trial were IRB00002556 (Austria), IRB00002091 (Czech Republic), IRB00007525 (Germany), IRB00004959 (Sweden) and IRB00002590 (Spain).”

MethodsFind in source

“Informed consent was obtained before the screening visit.”

MethodsFind in source

“The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH-GCP).”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals from named IRBs and informed consent are clearly documented.

Evidence

“The IRBs approving the trial were IRB00002556 (Austria), IRB00002091 (Czech Republic), IRB00007525 (Germany), IRB00004959 (Sweden) and IRB00002590 (Spain).”

MethodsFind in source

“Informed consent was obtained before the screening visit.”

MethodsFind in source

The investigational product LM11A-31 is described with its formulation (oral capsules) and dosing regimen (200 mg or 400 mg twice daily). The placebo is also described. Software tools are identified, including SPM12 and CAT12, with a link to preprocessing scripts. Antibodies, cell lines, and mycoplasma testing are not applicable as this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (LM11A-31) is identified with dose and regimen, and the software used for analysis is identified.

Evidence

“A single administration of medication consisted of the following: two capsules of 200 mg placebo (placebo group), one capsule of 200 mg LM11A-31 and one capsule of 200 mg placebo (200 mg LM11A-31 group) or two capsules of 200 mg LM11A-31 (400 mg LM11A-31 group).”

MethodsFind in source

“Wrapper scripts to call SPM12 and CAT12 functions for MRI and PET preprocessing are available at https://github.com/hayleyshanks/Longitudinal-MRI-PET-preproc”

Data availabilityFind in source

PASSReviewer 2· 90% conf

The investigational product LM11A-31 is adequately identified, and software tools are identified.

Evidence

MethodsFind in source

“Wrapper scripts to call SPM12 and CAT12 functions for MRI and PET preprocessing are available at https://github.com/hayleyshanks/Longitudinal-MRI-PET-preproc”

Data availabilityFind in source

The paper names statistical tests (e.g., Wilcoxon rank sum, Kruskal-Wallis, Fisher's exact, voxel-wise ANOVA) and reports effect sizes with 95% CIs for key outcomes. P-values are reported as exact values for many comparisons, though some are reported as thresholds (e.g., P < 0.05). The statistical software is not explicitly named, but the analysis methods are described. Data presentation includes box plots with per-group n. Mathematical plausibility is not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, effect sizes with confidence intervals are reported, and the analysis is appropriate for a clinical trial.

Evidence

“Significant differences in median change between placebo and LM11A-31 groups were investigated using Wilcoxon rank sum tests with 95% bootstrap CIs from 5,000 bootstrap iterations.”

Statistical analysisFind in source

“The difference in median annual percent change of Aβ42 in the LM11A-31 group relative to the placebo group was −6.98% (95% CI, −14.22% to −1.45%).”

ResultsFind in source

“P < 0.05 for each”

ResultsFind in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

“Significant differences in median change between placebo and LM11A-31 groups were investigated using Wilcoxon rank sum tests with 95% bootstrap CIs from 5,000 bootstrap iterations.”

Statistical analysisFind in source

“LM11A-31 significantly slowed longitudinal increases in Aβ42 compared to placebo (Fig. ; P rank sum = 0.037).”

ResultsFind in source

“The difference in median annual percent change of Aβ42 in the LM11A-31 group relative to the placebo group was −6.98% (95% CI, −14.22% to −1.45%).”

ResultsFind in source

The data availability statement says data can be shared in compliance with regulations but does not specify a concrete mechanism or platform, only directing requests to corresponding authors. This is reported_but_inadequate. The custom code for majority count statistics is not publicly available, but wrapper scripts for MRI/PET preprocessing are on GitHub. Repository deposit and accession numbers are not applicable for patient-level data.

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The data availability statement is vague, and the custom code is not publicly available, though some preprocessing scripts are shared.

Evidence

“Data files containing pseudonymized participant data (baseline characteristics, raw data used to conduct primary and exploratory endpoint analyses reported in this article) can be shared in compliance with current data protection regulations by the EU. All requests for data access should be directed to the corresponding authors.”

Data availabilityFind in source

“The custom code to perform the majority count statistics and Monte Carlo simulations (Fig. ) developed by K.C. is not publicly available but may be made available to qualified researchers on reasonable request to the corresponding authors.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data availability is stated but vague, while code availability is partially addressed.

Evidence

paraphrase[Data availability]

“Data files containing pseudonymized participant data ... can be shared in compliance with current data protection regulations by the EU. All requests for data access should be directed to the corresponding authors.”

Data availabilityFind in source

Methods are detailed enough for replication. The trial is registered with EU and ClinicalTrials.gov numbers. A reporting summary is mentioned. All outcomes, including non-significant ones, are reported. Limitations are discussed. Conclusions are proportional to the evidence. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent about methods, limitations, and funding, and reports all outcomes including null results.

Evidence

“EU Clinical Trials registration: 2015-005263-16 (https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005263-16) ; ClinicalTrials.gov registration: NCT03069014 (https://clinicaltrials.gov/ct2/show/NCT03069014) .”

AbstractFind in source

“By design, this phase 2a safety trial had several limitations for detecting cognitive effects, including a small number of participants and a relatively short 26-week study duration .”

DiscussionFind in source

“This trial was sponsored and funded by PharmatrophiX (Menlo Park, California) and the National Institute on Aging (NIA AD pilot trial 1R01AG051596).”

AcknowledgementsFind in source

PASSReviewer 2· 90% conf

The paper is transparent with trial registration, detailed methods, discussion of limitations, and proportional conclusions.

Evidence

paraphrase[Abstract]

“EU Clinical Trials registration: 2015-005263-16 ... ClinicalTrials.gov registration: NCT03069014”

paraphrase[Discussion]

“By design, this phase 2a safety trial had several limitations for detecting cognitive effects, including a small number of participants and a relatively short 26-week study duration.”

“This trial was sponsored and funded by PharmatrophiX (Menlo Park, California) and the National Institute on Aging (NIA AD pilot trial 1R01AG051596).”

AcknowledgementsFind in source

Registered (2 IDs: ClinicalTrials.gov, EudraCT). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 102 references by DOI: 101 verified — 1 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, other.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and generally well-reported, but readers should weigh the vague data availability statement and the lack of public custom code as limitations for reproducibility. The minor inconsistency in participant numbers (242 vs 241) and threshold p-values are minor reporting issues that could warrant a correction or clarification.

1.
HIGHdata code
In the Data availability section, specify a concrete data access mechanism (e.g., a data access committee or a platform like Vivli) and the conditions for access, rather than just directing requests to corresponding authors.
The current statement is vague and does not meet reproducibility standards for a data-driven clinical trial.
2.
HIGHdata code
In the Code availability section, make the custom code for majority count statistics and Monte Carlo simulations publicly available in a repository with a DOI, or provide a detailed algorithm description.
The custom code is essential for reproducing the primary analysis and is currently only available on request.
3.
MEDIUMstatistics
In the Statistical analysis section, explicitly name the statistical software used (e.g., R version, SPSS) and provide version numbers for SPM12 and CAT12.
Software identification is a standard reproducibility requirement and is currently missing.
4.
MEDIUMstatistics
In the Results section, report exact p-values for all comparisons instead of thresholds like 'P < 0.05'.
Exact p-values improve precision and allow readers to assess the strength of evidence.
5.
MEDIUMreporting
In the Abstract and Results, clarify the discrepancy between 242 participants (abstract) and 241 randomized (results), specifying the safety vs ITT populations.
The inconsistency could confuse readers and should be resolved for clarity.
6.
MEDIUMreporting
In the Results, clarify the difference between 'completed the study as outlined' and 'completed the 26-week visit'.
The distinction is not immediately clear and should be defined for transparency.
7.
MEDIUMreporting
In the Methods or supplementary, reference the CONSORT checklist and provide a CONSORT flow diagram with exact numbers for each stage, including screen failures.
Explicitly following CONSORT improves reporting completeness and is expected for RCTs.
8.
MEDIUMreporting
In the Methods, provide more detail on the randomization sequence generation (e.g., random number generator used) and clarify outlier handling for the primary analysis.
These details are important for reproducibility and are currently only partially described.
9.
LOWreporting
In the Data availability statement, clarify whether data can be shared with researchers outside the EU and under what conditions.
The current statement is ambiguous about international data sharing.
10.
LOWreporting
In Table 2, define 'freq' more clearly in the footnote.
The current definition could be clearer to avoid misinterpretation.
11.
LOWreporting
In the Discussion, consider discussing the potential impact of the lack of diversity in the study population on generalizability.
Addressing diversity would strengthen the discussion of limitations.
12.
LOWreporting
In the Data availability statement, consider providing a data dictionary for the variables.
A data dictionary would facilitate data reuse and reproducibility.

Full text (86,180 chars · analyzed ~87%, head + tail)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.

Shanks HRC, Chen K, Reiman EM, Blennow K, Cummings JL, Massa SM, Longo FM, Börjesson-Hanson A, Windisch M, Schmitz TW

Read full text (PMC)

DOI

10.1038/s41591-024-02977-w

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/e3b5deee-2551-4be8-bcea-99860f754a0a" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/e3b5deee-2551-4be8-bcea-99860f754a0a/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

dce37d8540171e76bda27641bbb110037d91a3ba36a19845b96925d6e52d7e9f

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim is based on surrogate biomarkers (CSF Aβ42, Aβ40, SNAP25, NG, YKL40, sMRI gray matter volume, FDG PET glucose metabolism) without demonstrating target engagement at the tested dose or citing validated evidence linking these surrogates to clinical outcomes. The paper acknowledges lack of direct p75NTR engagement markers and no significant cognitive effects.
“Currently, in vivo markers of direct p75 NTR engagement in humans are lacking. However, the CSF, sMRI and PET biomarkers included in this trial were prespecified on the basis of preclinical research examining pathways and mechanisms regulated by p75 NTR”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effects are small percentage changes in biomarkers (e.g., Aβ42 -6.98%, SNAP25 -19.20%, NG -9.17%) with no anchor to clinical meaningfulness. The paper states no significant cognitive effects and acknowledges the study was not powered for cognitive outcomes.
“Although the effect was not statistically significant, 26-week treatment with LM11A-31 produced up to 50% slowing of cognitive decline relative to that observed in the placebo group”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit5 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

Other integrity concernAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing extensive prior work on p75NTR biology and LM11A-31, and clearly links this to the study's rationale and hypotheses.

Evidence

Introduction ¶1Find in source

IntroductionFind in source

“Despite its fundamental functional role in neural and developmental cell biology, the therapeutic potential for targeted modulation of p75 NTR in humans has not been tested.”

Introduction ¶6Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing extensive prior work on p75NTR and LM11A-31, and clearly links this to the study's rationale and hypothesis.

Evidence

paraphrase[Introduction, paragraphs 1-6]

“Over the past two decades, multiple lines of evidence have converged on the p75 neurotrophin receptor (p75NTR) as a promising deep biology target for modifying neuronal dysfunction and degeneration in AD.”

paraphrase[Introduction, final paragraph]

“A limitation of these strategies is that they each target a narrow set of AD-related pathophysiological processes.”

Introduction ¶1Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous, with clear randomization, blinding, sample size determination, and pre-specified inclusion/exclusion criteria.

Evidence

MethodsFind in source

“The sponsor’s personnel, study sites’ personnel, participants and caregivers were blinded to the assigned treatment.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, sample size determination, and pre-specified inclusion/exclusion criteria.

Evidence

MethodsFind in source

“The sponsor’s personnel, study sites’ personnel, participants and caregivers were blinded to the assigned treatment.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper reports key demographic and clinical characteristics of the trial participants, including age, sex, race, and health status.

Evidence

“Age | 72 (8.00) | 72 (7.75) | 72 (8.00) | H = 0.81 | 0.67 |”

Table 1Find in source

“Males, n (%) | 35 (43.2) | 38 (48.7) | 40 (48.2) | χ 2 = 0.60 | 0.74 |”

Table 1Find in source

“General health status acceptable for participation in a 26-week clinical trial”

MethodsFind in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, and key disease-related variables.

Evidence

“Age | 72 (8.00) | 72 (7.75) | 72 (8.00) | H = 0.81 | 0.67 |”

Table 1Find in source

“Screening MMSE | 22 (4.00) | 22 (5.00) | 23 (4.00) | H = 3.19 | 0.20 |”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper reports named IRB approvals for each participating country and states that informed consent was obtained.

Evidence

“The IRBs approving the trial were IRB00002556 (Austria), IRB00002091 (Czech Republic), IRB00007525 (Germany), IRB00004959 (Sweden) and IRB00002590 (Spain).”

MethodsFind in source

“Informed consent was obtained before the screening visit.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals from named IRBs and informed consent are clearly documented.

Evidence

“The IRBs approving the trial were IRB00002556 (Austria), IRB00002091 (Czech Republic), IRB00007525 (Germany), IRB00004959 (Sweden) and IRB00002590 (Spain).”

MethodsFind in source

“Informed consent was obtained before the screening visit.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (LM11A-31) is identified with dose and regimen, and the software used for analysis is identified.

Evidence

MethodsFind in source

“Wrapper scripts to call SPM12 and CAT12 functions for MRI and PET preprocessing are available at https://github.com/hayleyshanks/Longitudinal-MRI-PET-preproc”

Data availabilityFind in source

PASSReviewer 2· 90% conf

The investigational product LM11A-31 is adequately identified, and software tools are identified.

Evidence

MethodsFind in source

“Wrapper scripts to call SPM12 and CAT12 functions for MRI and PET preprocessing are available at https://github.com/hayleyshanks/Longitudinal-MRI-PET-preproc”

Data availabilityFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, effect sizes with confidence intervals are reported, and the analysis is appropriate for a clinical trial.

Evidence

“Significant differences in median change between placebo and LM11A-31 groups were investigated using Wilcoxon rank sum tests with 95% bootstrap CIs from 5,000 bootstrap iterations.”

Statistical analysisFind in source

“The difference in median annual percent change of Aβ42 in the LM11A-31 group relative to the placebo group was −6.98% (95% CI, −14.22% to −1.45%).”

ResultsFind in source

“P < 0.05 for each”

ResultsFind in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

“Significant differences in median change between placebo and LM11A-31 groups were investigated using Wilcoxon rank sum tests with 95% bootstrap CIs from 5,000 bootstrap iterations.”

Statistical analysisFind in source

“LM11A-31 significantly slowed longitudinal increases in Aβ42 compared to placebo (Fig. ; P rank sum = 0.037).”

ResultsFind in source

“The difference in median annual percent change of Aβ42 in the LM11A-31 group relative to the placebo group was −6.98% (95% CI, −14.22% to −1.45%).”

ResultsFind in source

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The data availability statement is vague, and the custom code is not publicly available, though some preprocessing scripts are shared.

Evidence

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data availability is stated but vague, while code availability is partially addressed.

Evidence

paraphrase[Data availability]

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent about methods, limitations, and funding, and reports all outcomes including null results.

Evidence

AbstractFind in source

“By design, this phase 2a safety trial had several limitations for detecting cognitive effects, including a small number of participants and a relatively short 26-week study duration .”

DiscussionFind in source

“This trial was sponsored and funded by PharmatrophiX (Menlo Park, California) and the National Institute on Aging (NIA AD pilot trial 1R01AG051596).”

AcknowledgementsFind in source

PASSReviewer 2· 90% conf

The paper is transparent with trial registration, detailed methods, discussion of limitations, and proportional conclusions.

Evidence

paraphrase[Abstract]

“EU Clinical Trials registration: 2015-005263-16 ... ClinicalTrials.gov registration: NCT03069014”

paraphrase[Discussion]

“By design, this phase 2a safety trial had several limitations for detecting cognitive effects, including a small number of participants and a relatively short 26-week study duration.”

“This trial was sponsored and funded by PharmatrophiX (Menlo Park, California) and the National Institute on Aging (NIA AD pilot trial 1R01AG051596).”

AcknowledgementsFind in source

Registered (2 IDs: ClinicalTrials.gov, EudraCT). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 102 references by DOI: 101 verified — 1 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, other.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
In the Data availability section, specify a concrete data access mechanism (e.g., a data access committee or a platform like Vivli) and the conditions for access, rather than just directing requests to corresponding authors.
The current statement is vague and does not meet reproducibility standards for a data-driven clinical trial.
2.
HIGHdata code
In the Code availability section, make the custom code for majority count statistics and Monte Carlo simulations publicly available in a repository with a DOI, or provide a detailed algorithm description.
The custom code is essential for reproducing the primary analysis and is currently only available on request.
3.
MEDIUMstatistics
In the Statistical analysis section, explicitly name the statistical software used (e.g., R version, SPSS) and provide version numbers for SPM12 and CAT12.
Software identification is a standard reproducibility requirement and is currently missing.
4.
MEDIUMstatistics
In the Results section, report exact p-values for all comparisons instead of thresholds like 'P < 0.05'.
Exact p-values improve precision and allow readers to assess the strength of evidence.
5.
MEDIUMreporting
In the Abstract and Results, clarify the discrepancy between 242 participants (abstract) and 241 randomized (results), specifying the safety vs ITT populations.
The inconsistency could confuse readers and should be resolved for clarity.
6.
MEDIUMreporting
In the Results, clarify the difference between 'completed the study as outlined' and 'completed the 26-week visit'.
The distinction is not immediately clear and should be defined for transparency.
7.
MEDIUMreporting
In the Methods or supplementary, reference the CONSORT checklist and provide a CONSORT flow diagram with exact numbers for each stage, including screen failures.
Explicitly following CONSORT improves reporting completeness and is expected for RCTs.
8.
MEDIUMreporting
In the Methods, provide more detail on the randomization sequence generation (e.g., random number generator used) and clarify outlier handling for the primary analysis.
These details are important for reproducibility and are currently only partially described.
9.
LOWreporting
In the Data availability statement, clarify whether data can be shared with researchers outside the EU and under what conditions.
The current statement is ambiguous about international data sharing.
10.
LOWreporting
In Table 2, define 'freq' more clearly in the footnote.
The current definition could be clearer to avoid misinterpretation.
11.
LOWreporting
In the Discussion, consider discussing the potential impact of the lack of diversity in the study population on generalizability.
Addressing diversity would strengthen the discussion of limitations.
12.
LOWreporting
In the Data availability statement, consider providing a data dictionary for the variables.
A data dictionary would facilitate data reuse and reproducibility.

Full text (86,180 chars · analyzed ~87%, head + tail)Analyzed: Aug 16, 2026